All In Biotech

Drug Trial Radar · NCT04820439

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection (HS627) and Perjeta ® in Healthy Male Subjects: a Randomized, Double-blind, Parallelity-controlled Study

Last checked: Nov 19, 2026Latest source record: Mar 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

88

Actual

Start

Oct 13, 2020

Primary completion

Feb 1, 2021

Study completion Mar 13, 2021

Sponsor

Lead sponsor
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was designed as a randomized, double-blind, parallelity-controlled study.Eighty-eight healthy male subjects (44 in each group) will be enrolled in this study.The aim of this clinical trial is to evaluate pharmacokinetic similarity between recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627) and Perjeta ® in a single intravenous infusion in healthy male subjects.

Conditions

  • Healthy Volunteers

Interventions

  • recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)Drug

    A single intravenous infusion of HS627 420mg

  • Perjeta ®Drug

    A single intravenous infusion of Perjeta ®420mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration versus time curve (AUC)0-∞Time frame: 150 days
  2. Area under the plasma concentration versus time curve (AUC)0-tTime frame: 150 days
  3. Peak Plasma Concentration (Cmax)Time frame: 150 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Phase I Clinical Research Center

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.